Viral infection and cancer: The nf-b/snail/rkip loop regulates target cell sensitivity to apoptosis by cytotoxic lymphocytes

Critical Reviews in Immunology

Volumn 30, Issue 1, 2010, Pages 31-46

  Bonavida, Benjamin ^a   Baritaki, Stavroula ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Raf 1 kinase inhibitor protein (RKIP); Resistance; Snail; TRAIL

Indexed keywords

FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SNAIL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; PEBP1 PROTEIN, HUMAN; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

APOPTOSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; VIRUS INFECTION; IMMUNOLOGY; METABOLISM; NEOPLASM;

APOPTOSIS; HUMANS; NEOPLASMS; NF-KAPPA B; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; T-LYMPHOCYTES, CYTOTOXIC; TRANSCRIPTION FACTORS; VIRUS DISEASES;

EID: 77950967102     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Cooper ELKauschke E Cossarizza A. Digging for innate immunity since Darwin and Metchnikoff. Bioessays 2002 Apr 24(4) 319-333.
2. Uthaisangsook S, Day NK, Bahna SL, Good RA, Haraguchi S. Innate immunity and its role against infections. Ann Allergy Asthma Immunol. 2002 Mar;88(3):253-64; quiz 65-6, 318.
3. Blach-Olszewska Z. Innate immunity: cells, receptors, and signaling pathways. Arch Immunol Ter Exp (Warsz). 2005 May-Jun;53(3):245-253.
4. Guermonprez P, Valladeau J, Zitvogel L, Tery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002;20: 621-667.
5. Janeway CA, Jr., Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216.
6. Rubin B. Natural immunity has signifcant impact on immune responses against cancer. Scand J Immunol. 2009 Mar;69(3):275-290.
7. Moretta L, Bottino C, Pende D, Vitale M, Mingari MC, Moretta A. Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunol Lett. 2005 Aug 15;100(1):7-13.
8. Biassoni R. Human natural killer receptors, co-receptors, and their ligands. Curr Protoc Immunol. 2009 Feb;Chapter 14:Unit 14.10.
9. Weck MM, Grunebach F, Werth D, Sinzger C, Bringmann A, Brossart P. TLR ligands diferentially afect uptake and presentation of cellular antigens. Blood. 2007 May 1;109(9):3890-3894.
10. Zeromski J, Mozer-Lisewska I, Kaczmarek M. Signifcance of Toll-like Receptors Expression in Tumor Growth and Spreading: A Short Review. Cancer Microenviron. 2008 Dec;1(1):37-42.
11. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376.
12. Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett. 2009;14(2):248-272.
13. Alder MN, Rogozin IB, Iyer LM, Glazko GV, Cooper MD, Pancer Z. Diversity and function of adaptive immune receptors in a jawless vertebrate. Science. 2005 Dec 23;310(5756):1970-1973.
14. Janeway C. Immunobiology. 6 ed. Oxford, UK: Garland Science, 2004.
15. Miller JF, Basten A, Sprent J, Cheers C. Interaction between lymphocytes in immune responses. Cell Immunol. 1971 Oct;2(5):469-495.
16. Vos Q, Lees A, Wu ZQ, Snapper CM, Mond JJ. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev. 2000 Aug;176:154-170.
17. Kranz DM, Pasternack MS, Eisen HN. Recognition and lysis of target cells by cytotoxic T lymphocytes. Fed Proc. 1987 Feb;46(2):309-312.
18. Arancia G, Malorni W, Donelli G. Cellular mechanisms of lymphocyte-mediated lysis of tumor cells. Ann Ist Super Sanita. 1990;26(3-4):369-384.
19. Goust JM. Cell-mediated immunity. Immunol Ser. 1990;50:195-215.
20. Stevenson HC, Stevenson GW. Immunomodulation of cancer with activated cytotoxic leukocytes. Prog Clin Biol Res. 1990;337:435-438.
21. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet. 2009 Mar 21;373(9668):1033-1040.
22. Knuth A, Wolfel T, Meyer zum Buschenfelde KH. T cell responses to human malignant tumours. Cancer Surv. 1992;13:39-52.
23. Jager E, Chen Y T, Drijfhout JW, Karbach J, Ringhofer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: defnition of human histocompatibil-ity leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998 Jan 19;187(2):265-270.
24. Stockert E, Jager E, Chen Y T, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med. 1998 Apr 20;187(8):1349-1354.
25. Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, Zerkowski HR, Heberer M, Spagnoli GC. Cancer/testis antigen expression and specifc cyto-toxic T lymphocyte responses in non small cell lung cancer. Int J Cancer. 2007 Jan 15;120(2):337-343.
26. Ichiki Y, Takenoyama M, Mizukami M, So T, Sugaya M, Yasuda M, So T, Hanagiri T, Sugio K, Yasumoto K. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J Immunol. 2004 Apr 15;172(8):4844-4850.
27. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ter. 2005 Feb;4(2):139-163.
28. Shresta S, Pham CT, Tomas DA, Graubert TA, Ley TJ. How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol. 1998 Oct;10(5):581-587.
29. Wilson NS, Dixit V, Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol. 2009 Apr;10(4):348-355.
30. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997 Aug 8;277(5327):818-821.
31. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999 Jul;104(2):155-162.
32. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 2003 Nov 24;22(53):8628-8633.
33. Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials. 2009 Jan;4(1):34-41.
34. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008 Jun-Aug;19(3-4):325-331.
35. Elrod HA, Sun SY. Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ter. 2008 Feb;7(2):163-173.
36. Oldenhuis CN, Stegehuis JH, Walenkamp AM, de Jong S, de Vries EG. Targeting TRAIL death receptors. Curr Opin Pharmacol. 2008 Aug;8(4):433-439.
37. Shankar S, Srivastava RK. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat. 2004 Apr;7(2):139-156.
38. Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, Petersson M. Tumor-induced immune dysfunction. Cancer Immunol Immunother. 1999 Oct;48(7):353-362.
39. Frost PJ, Butterfeld LH, Dissette VB, Economou JS, Bonavida B. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specifc CTL cultures. J Immunol. 2001 Mar 1;166(5):3564-3573.
40. Schwinn N, Vokhminova D, Sucker A, Textor S, Striegel S, Moll I, Nausch N, Tuettenberg J, Steinle A, Cerwenka A, Schadendorf D, Paschen A. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-defcient melanoma by natural killer cells. Int J Cancer. 2009 Apr 1;124(7):1594-1604.
41. Classen CF, Falk CS, Friesen C, Fulda S, Herr I, Debatin KM. Natural killer resistance of a drug-resistant leukemia cell line, mediated by up-regulation of HLA class I expression. Haematologica. 2003 May;88(5):509-521.
42. Huang Y, Obholzer N, Fayad R, Qiao L. Turning on/of tumor-specifc CTL response during progressive tumor growth. J Immunol. 2005 Sep 1;175(5):3110-3116.
43. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res. 2006 Jul 1;12(13):3890-3895.
44. Frey AB, Monu N. Signaling defects in anti-tumor T cells. Immunol Rev. 2008 Apr;222:192-205.
45. Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. Oncogene. 2006 Oct 30;25(51):6758-6780.
46. Inoue A, Seidel MG, Wu W, Kamizono S, Ferrando AA, Bronson RT, Iwasaki H, Akashi K, Morimoto A, Hitzler JK, Pestina TI, Jackson CW, Tanaka R, Chong MJ, McKinnon PJ, Inukai T, Grosveld GC, Look AT. Slug, a highly conserved zinc fnger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. Cancer Cell. 2002 Oct;2(4):279-288.
47. Bours V, Bentires-Alj M, Hellin AC, Viatour P, Robe P, Delhalle S, Benoit V, Merville M P. Nuclear factor-kappa B, cancer, and apoptosis. Biochem Pharmacol. 2000 Oct 15;60(8):1085-1089.
48. Arlt A, Schafer H. NFkappaB-dependent chemore-sistance in solid tumors. Int J Clin Pharmacol Ter. 2002 Aug;40(8):336-347.
49. Lu T, Stark GR. Cytokine overexpression and constitutive NFkappaB in cancer. Cell Cycle. 2004 Sep;3(9):1114-1117.
50. Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA, Bonavida B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ter. 2007 Apr;6(4):1387-1399.
51. Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, Penichet ML, Jazirehi AR, Palladino M, Bonavida B. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol. 2008 May 1;180(9):6199-6210.
52. Katsman A, Umezawa K, Bonavida B. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. Drug Resist Updat. 2007 Feb-Apr;10(1-2):1-12.
53. Aggarwal BB, Bhardwaj U, Takada Y. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors. Vitam Horm. 2004;67:453-483.
54. Wajant H. TRAIL and NFkappaB signaling-a complex relationship. Vitam Horm. 2004;67:101-132.
55. Fan Y, Dutta J, Gupta N, Fan G, Gelinas C. Regulation of programmed cell death by NF-kappaB and its role in tumorigenesis and therapy. Adv Exp Med Biol. 2008;615:223-250.
56. Ravi R, Bedi GC, Engstrom LW, Zeng Q, Mookerjee B, Gelinas C, Fuchs EJ, Bedi A.Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol. 2001 Apr;3(4):409-416.
57. Chen X, Kandasamy K, Srivastava RK. Diferential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res. 2003 Mar 1;63(5):1059-1066.
58. Shetty S, Graham BA, Brown JG, Hu X, Vegh-Yarema N, Harding G, Paul J T, Gibson SB. Transcription factor NF-kappaB diferentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol. 2005 Jul;25(13):5404-5416.
59. Wang H, Hertlein E, Bakkar N, Sun H, Acharyya S, Wang J, Carathers M, Davuluri R, Guttridge DC.NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofbrillar genes. Mol Cell Biol. 2007 Jun;27(12):4374-4387.
60. Garban HJ, Bonavida B. Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J Immunol. 2001 Jul 1;167(1):75-81.
61. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene. 2006 Feb 23;25(8):1125-1142.
62. Seligson DB, Hongo F, Huerta-Yepez S, Mizutani Y, Miki T, Yu H, Horvath S, Chia D, Goodglick L, Bonavida B. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin Cancer Res. 2007 Oct 15;13(20):6056-6063.
63. Castellano G, Torrisi E, Ligresti G, Malaponte G, Militello L, Russo AE, McCubrey JA, Canevari S, Libra M. Te involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle. 2009 May 1;8(9):1367-1372.
64. Huerta-Yepez S, Vega M, Escoto-Chavez SE, Murdock B, Sakai T, Baritaki S, Bonavida B. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. Nitric Oxide. 2009 Feb;20(1):39-52.
65. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007 Aug;1773(8):1263-1284.
66. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, Sedivy JM, Kolch W. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature. 1999 Sep 9;401(6749):173-177.
67. Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W, Sedivy JM. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol. 2001 Nov;21(21):7207-7217.
68. Lorenz K, Lohse MJ, Quitterer U. Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature. 2003 Dec 4;426(6966):574-579.
69. Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn R, Chinnaiyan AM, Yao Z, Keller ET. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate. 2006 Feb 15;66(3):248-256.
70. Al-Mulla F, Hagan S, Behbehani AI, Bitar MS, George SS, Going JJ, Garcia JJ, Scott L, Fyfe N, Murray GI, Kolch W. Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J Clin Oncol. 2006 Dec 20;24(36):5672-5679.
71. Minoo P, Zlobec I, Baker K, Tornillo L, Terracciano L, Jass JR, Lugli A. Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am J Clin Pathol. 2007 May;127(5):820-827.
72. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhof AK. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res. 2004 Aug 1;64(15):5186-5192.
73. Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B, Garcia JJ, Kolch W. Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res. 2005 Oct 15;11(20):7392-7397.
74. Eves EM, Shapiro P, Naik K, Klein UR, Trakul N, Rosner MR. Raf kinase inhibitory protein regulates aurora B kinase and the spindle checkpoint. Mol Cell. 2006 Aug;23(4):561-574.
75. Vagnarelli P, Earnshaw WC. Chromosomal passengers: the four-dimensional regulation of mitotic events. Chromosoma. 2004 Nov;113(5):211-222.
76. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB, Darnowski J, Pantazis P, Wyche J, Fu Z, Kitagwa Y, Keller ET, Sedivy JM, Yeung KC. RKIP sensitizes prostate and breast cancer cells to drug-induced apop-tosis. J Biol Chem. 2004 Apr 23;279(17):17515-17523.
77. Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkins lym-phoma B cells by Rituximab. Cancer Res. 2007 Oct 1;64(19):7117-7126.
78. Baritaki S, Katsman A, Chatterjee D, Yeung KC, Spandidos DA, Bonavida B. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the meta-static suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. J Immunol. 2007 Oct 15;179(8):5441-5453.
79. Beach S, Tang H, Park S, Dhillon AS, Keller ET, Kolch W, Yeung KC. Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene. 2008 Apr 3;27(15):2243-2248.
80. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol. 2002 Mar;3(3):155-166.
81. Peinado H, Portillo F, Cano A. Transcriptional regulation of cadherins during development and carcino-genesis. Int J Dev Biol. 2004;48(5-6):365-375.
82. Ohkubo T, Ozawa M. Te transcription factor Snail downregulates the tight junction components independently of E-cadherin downregulation. J Cell Sci. 2004 Apr 1;117(Pt 9):1675-1685.
83. Yokoyama K, Kamata N, Hayashi E, Hoteiya T, Ueda N, Fujimoto R, Nagayama M. Reverse correlation of E-cadherin and snail expression in oral squamous cell carcinoma cells in vitro. Oral Oncol. 2001 Jan;37(1):65-71.
84. Miyoshi A, Kitajima Y, Kido S, Shimonishi T, Matsuyama S, Kitahara K, Miyazaki K. Snail accelerates cancer invasion by upregulating MMP expression and is associated with poor prognosis of hepatocellular carcinoma. Br J Cancer. 2005 Jan 31;92(2):252-258.
85. Zha YH, He JF, Mei YW, Yin T, Mao L. Zinc-fnger transcription factor snail accelerates survival, migration and expression of matrix metalloproteinase-2 in human bone mesenchymal stem cells. Cell Biol Int. 2007 Oct;31(10):1089-1096.
86. Kajita M, McClinic KN, Wade PA. Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol Cell Biol. 2004 Sep;24(17):7559-7566.
87. Vega S, Morales AV, Ocana OH, Valdes F, Fabregat I, Nieto MA. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev. 2004 May 15;18(10):1131-1143.
88. Zhuo W, Wang Y, Zhuo X, Zhang Y, Ao X, Chen Z. Knockdown of Snail, a novel zinc fnger transcription factor, via RNA interference increases A549 cell sensitivity to cisplatin via JNK/mitochondrial pathway. Lung Cancer. 2008 Oct;62(1):8-14.
89. Escriva M, Peiro S, Herranz N, Villagrasa P, Dave N, Montserrat-Sentis B, Murray SA, Franci C, Gridley T, Virtanen I, Garcia de Herreros A. Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis. Mol Cell Biol. 2008 Mar;28(5):1528-1540.
90. Toyama T, Zhang Z, Iwase H, Yamashita H, Ando Y, Hamaguchi M, Mizutani M, Kondo N, Fujita T, Fujii Y, Iwata H. Low expression of the snail gene is a good prognostic factor in node-negative invasive ductal carcinomas. Jpn J Clin Oncol. 2006 Jun;36(6):357-363.
91. Yang MH, Chang SY, Chiou SH, Liu CJ, Chi CW, Chen PM, Teng SC, Wu KJ. Overexpression of NBS1 induces epithelial-mesenchymal transition and co-expression of NBS1 and Snail predicts metastasis of head and neck cancer. Oncogene. 2007 Mar 1;26(10):1459-1467.
92. Yin T, Wang C, Liu T, Zhao G, Zha Y, Yang M. Expression of snail in pancreatic cancer promotes metastasis and chemoresistance. J Surg Res. 2007 Aug;141(2):196-203.
93. Blechschmidt K, Sassen S, Schmalfeldt B, Schuster T, Hofer H, Becker KF. Te E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br J Cancer. 2008 Jan 29;98(2):489-495.
94. Barbera MJ, Puig I, Dominguez D, Julien-Grille S, Guaita-Esteruelas S, Peiro S, Baulida J, Franci C, Dedhar S, Larue L, Garcia de Herreros A. Regulation of Snail transcription during epithelial to mesenchy-mal transition of tumor cells. Oncogene. 2004 Sep 23;23(44):7345-7354.
95. Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, van Roy F, Dargemont C, de Herreros AG, Bellacosa A, Larue L. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene. 2007 Nov 22;26(53):7445-7456.
96. Peiro S, Escriva M, Puig I, Barbera MJ, Dave N, Herranz N, Larriba MJ, Takkunen M, Franci C, Munoz A, Virtanen I, Baulida J, Garcia de Herreros A. Snail1 transcriptional repressor binds to its own promoter and controls its expression. Nucleic Acids Res. 2006;34(7):2077-2084.
97. Palmer MB, Majumder P, Cooper JC, Yoon H, Wade PA, Boss JM. Yin yang 1 regulates the expression of snail through a distal enhancer. Mol Cancer Res. 2009 Feb;7(2):221-229.
98. Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B. Inhibition of epithelial to mesenchymal transition (EMT) in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: Pivotal roles of Snail repression and RKIP induction. Oncogene. 2009 Oct 8;28(40):3573-3585.
99. Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, Minn AJ, Rosner MR. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. Embo J. 2009 Feb 18;28(4):347-358.
100. Ludwig H, Khayat D, Giaccone G, Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer. 2005 Nov 1;104(9):1794-1807.
101. Sayers TJ, Murphy WJ. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother. 2006 Jan;55(1):76-84.
102. Chen JJ, Chou CW, Chang YF, Chen CC. Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation. J Immunol. 2008 Jun 15;180(12):8030-8039.
103. Huerta-Yepez S, Vega M, Jazirehi A, Garban H, Hongo F, Cheng G, Bonavida B. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene. 2004 Jun 24;23(29):4993-5003.
104. Ng CP, Bonavida B. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Mol Cancer Ter. 2002 Oct;1(12):1051-1058.